The PRAEGNANT study did not specify which cyclin-dependent kinase 4 and 6 inhibitor was used, but the data were similar to those of other studies, with neutropenia, leukopenia, diarrhoea, and asthenia being the most frequent adverse effects. Here, CDK4 is linked to asthenia.